Dr. Rodriguez on Systemic Therapy in Salivary Gland Cancer

Video

Cristina P. Rodriguez, MD, hematology oncologist, University of Washington School of Medicine in Seattle, discusses the emerging role of systemic therapy for patients with salivary gland cancer.

Cristina P. Rodriguez, MD, hematology oncologist, University of Washington School of Medicine in Seattle, discusses the emerging role of systemic therapy for patients with salivary gland cancers.

These are very rare malignancies that are also biologically diverse with 24 subtypes, Rodriguez explains. The challenge with treating these patients with chemotherapy is that there are not enough data from clinical trials to demonstrate its role.

Despite the lack of evidence, there are other agents that elicit activity in these tumors, including platinum-based therapies—whether alone or in combination. Immune checkpoint inhibitors may also have a role in this field. Use of next-generation sequencing might help identify subtypes that have therapeutic targets, she adds.

Related Videos
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD
Vikram M. Narayan, MD
C. Ola Landgren, MD, PhD
Timothy Yap, MBBS, PhD, FRCP
Muhamed Baljevic, MD, FACP
Kathleen A. Dorritie, MD
David L. Porter, MD, director, Cell Therapy and Transplant, Jodi Fisher Horowitz Professor in Leukemia Care Excellence, Penn Medicine
Muhamed Baljevic, MD